|
|
||||||||
Departments of Structural Biology, and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
KIR3DL1 is an inhibitory HLA-B receptor of human NK and T cells that exhibits genetic and phenotypic polymorphism. KIR3DL1*004, a common allotype, cannot be detected on the surface of PBLs using the KIR3DL1-specific Ab DX9. The nature of this phenotype was investigated through comparison of 3DL1*004 with 3DL1*002, an allele giving high DX9 binding to cell surfaces. Analysis of Jurkat T cell transfectants with 3DL1*004 cDNA showed that 3DL1*004 is poorly expressed at the cell surface, but detectable intracellularly. Analysis of recombinant mutants made between 3DL1*004 and 3DL1*002 showed that polymorphism in Ig domains 0 and 1 (D0 and D1) causes the intracellular retention of 3DL1*004. Reciprocal point mutations were introduced into 3DL1*004 and 3DL1*002 at positions 44 and 86 of the D0 domain, where 3DL1*004 has unique residues, and at position 182 of the D1 domain, where 3DL1*004 resembles 3DL1*005, an allotype giving low DX9-binding phenotype. Leucine 86 in 3DL1*004 is the principal cause of its intracellular retention, with a secondary and additive contribution from serine 182. By contrast, glycine 44, which is naturally present in 3DL1*004, slightly increased cell surface expression when introduced into 3DL1*002. In 3DL1*004, the presence of leucine at position 86 corrupts the WSXPS motif implicated in proper folding of the KIR D0 Ig-like domain. This study demonstrates how a difference between KIR3DL1 allotypes in the D0 domain profoundly affects cell surface expression and function.
This article has been cited by other articles:
![]() |
B. A. Foley, D. D. Santis, E. Van Beelen, L. J. Lathbury, F. T. Christiansen, and C. S. Witt The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations Blood, July 15, 2008; 112(2): 435 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Thomas, E. Yamada, G. Alter, M. P. Martin, A. A. Bashirova, P. J. Norman, M. Altfeld, P. Parham, S. K. Anderson, D. W. McVicar, et al. Novel KIR3DL1 Alleles and Their Expression Levels on NK Cells: Convergent Evolution of KIR3DL1 Phenotype Variation? J. Immunol., May 15, 2008; 180(10): 6743 - 6750. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kim, J. B. Sunwoo, L. Yang, T. Choi, Y.-J. Song, A. R. French, A. Vlahiotis, J. F. Piccirillo, M. Cella, M. Colonna, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency PNAS, February 26, 2008; 105(8): 3053 - 3058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yu, G. Heller, J. Chewning, S. Kim, W. M. Yokoyama, and K. C. Hsu Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands J. Immunol., November 1, 2007; 179(9): 5977 - 5989. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Pascal, E. Yamada, M. P. Martin, G. Alter, M. Altfeld, J. A. Metcalf, M. W. Baseler, J. W. Adelsberger, M. Carrington, S. K. Anderson, et al. Detection of KIR3DS1 on the Cell Surface of Peripheral Blood NK Cells Facilitates Identification of a Novel Null Allele and Assessment of KIR3DS1 Expression during HIV-1 Infection J. Immunol., August 1, 2007; 179(3): 1625 - 1633. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cooley, F. Xiao, M. Pitt, M. Gleason, V. McCullar, T. L. Bergemann, K. L. McQueen, L. A. Guethlein, P. Parham, and J. S. Miller A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature Blood, July 15, 2007; 110(2): 578 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ruggeri, A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood, July 1, 2007; 110(1): 433 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Estefania, R. Flores, N. Gomez-Lozano, H. Aguilar, M. Lopez-Botet, and C. Vilches Human KIR2DL5 Is an Inhibitory Receptor Expressed on the Surface of NK and T Lymphocyte Subsets J. Immunol., April 1, 2007; 178(7): 4402 - 4410. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Thananchai, G. Gillespie, M. P. Martin, A. Bashirova, N. Yawata, M. Yawata, P. Easterbrook, D. W. McVicar, K. Maenaka, P. Parham, et al. Cutting Edge: Allele-Specific and Peptide-Dependent Interactions between KIR3DL1 and HLA-A and HLA-B J. Immunol., January 1, 2007; 178(1): 33 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. O'Connor, K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner Functional Polymorphism of the KIR3DL1/S1 Receptor on Human NK Cells J. Immunol., January 1, 2007; 178(1): 235 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. VandenBussche, S. Dakshanamurthy, P. E. Posch, and C. K. Hurley A Single Polymorphism Disrupts the Killer Ig-Like Receptor 2DL2/2DL3 D1 Domain J. Immunol., October 15, 2006; 177(8): 5347 - 5357. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Carr, M. J. Pando, and P. Parham KIR3DL1 Polymorphisms That Affect NK Cell Inhibition by HLA-Bw4 Ligand J. Immunol., October 15, 2005; 175(8): 5222 - 5229. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Leung, R. Iyengar, B. Triplett, V. Turner, F. G. Behm, M. S. Holladay, J. Houston, and R. Handgretinger Comparison of Killer Ig-Like Receptor Genotyping and Phenotyping for Selection of Allogeneic Blood Stem Cell Donors J. Immunol., May 15, 2005; 174(10): 6540 - 6545. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Draghi, N. Yawata, M. Gleimer, M. Yawata, N. M. Valiante, and P. Parham Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I Blood, March 1, 2005; 105(5): 2028 - 2035. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Caligiuri, A. Velardi, D. A. Scheinberg, and I. M. Borrello Immunotherapeutic Approaches for Hematologic Malignancies Hematology, January 1, 2004; 2004(1): 337 - 353. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |